Israeli R S, Miller W H, Su S L, Samadi D S, Powell C T, Heston W D, Wise G J, Fair W R
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
J Urol. 1995 Mar;153(3 Pt 1):573-7. doi: 10.1016/s0022-5347(01)67651-1.
We developed a polymerase chain reaction based assay enabling sensitive detection of hematogenous tumor cell dissemination in patients with prostate cancer. We performed "nested polymerase chain reaction," amplifying messenger ribonucleic acid sequences unique to prostate specific antigen (PSA) and to the prostate specific membrane antigen, and compared the respective results. Prostatic tumor cells were detected in 2 of 30 patients (6.7%) by polymerase chain reaction with PSA derived primers, while prostate specific membrane primers detected tumor cells in 19 (63.3%). All 16 negative controls had negative PSA and prostate specific membrane polymerase chain reaction. Assays were repeated to confirm results, and polymerase chain reaction products were verified by deoxyribonucleic acid sequencing and Southern analysis. Patients harboring circulating prostatic tumor cells as detected by prostate specific membrane and not by PSA polymerase chain reaction included 7 of 13 previously treated by radical prostatectomy who had nonmeasurable serum PSA levels at the time of this assay. The significance of these findings with respect to future disease recurrence and progression will be investigated.
我们开发了一种基于聚合酶链反应的检测方法，能够灵敏地检测前列腺癌患者血行转移的肿瘤细胞。我们进行了“巢式聚合酶链反应”，扩增前列腺特异性抗原（PSA）和前列腺特异性膜抗原特有的信使核糖核酸序列，并比较各自的结果。使用源自PSA的引物通过聚合酶链反应在30例患者中的2例（6.7%）检测到前列腺肿瘤细胞，而使用前列腺特异性膜引物在19例（63.3%）检测到肿瘤细胞。所有16个阴性对照的PSA和前列腺特异性膜聚合酶链反应均为阴性。重复检测以确认结果，并通过脱氧核糖核酸测序和Southern分析验证聚合酶链反应产物。通过前列腺特异性膜而非PSA聚合酶链反应检测到循环前列腺肿瘤细胞的患者中，有7例曾接受根治性前列腺切除术，在此次检测时血清PSA水平不可测。这些发现对于未来疾病复发和进展的意义将进行研究。
